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Abstract
Objective. To evaluate the impact of postoperative radiother-
apy (PORT) and chemotherapy on survival in salivary gland
cancer (SGC) treated with curative-intent local resection
and neck dissection.
Study Design. Retrospective population-based cohort study.
Setting. National Cancer Database.
Subjects and Methods. Patients with SGC who were under-
going surgery were identified from the National Cancer
Database between 2004 and 2013. Neck dissection remov-
ing a minimum of 10 lymph nodes was required. Because
PORT violated the proportional hazards assumption, this
variable was treated as a time-dependent covariate.
Results. Overall, 4145 cases met inclusion criteria (median
follow-up, 54 months). PORT was associated with improved
overall survival in multivariable analysis, both 9 months
from diagnosis (hazard ratio [HR], 0.26; 95% CI, 0.20-0.34;
P\ .001) and .9 months (HR, 0.75; 95% CI, 0.66-0.86; P\
.001). In propensity score–matched cohorts, 5-year overall
survival was 67.1% and 60.6% with PORT and observation,
respectively (P\ .001). Similar results were observed in land-
mark analysis of patients surviving at least 6 months following
diagnosis. Adjuvant chemotherapy was not associated with
improved survival (HR, 1.15; 95% CI, 0.99-1.34; P = .06).
Conclusion. PORT, but not chemotherapy, is associated with
improved survival among patients with SGC for whom neck
dissection was deemed necessary. These results are not
applicable to low-risk SGCs not requiring neck dissection.
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S
alivary gland cancer (SGC) is a rare malignancy
accounting for approximately 3% to 6% of all head
and neck cancers.1 SGC can arise from the major and
minor salivary glands throughout the head and neck, leading
to diverse clinical presentations. Biologically, SGC is highly
heterogeneous, with 20 histological subtypes recognized by
the 2017 World Health Organization classification system.2
For these reasons, the diagnosis and treatment of SGC can
be challenging, even at high-volume tertiary referral centers.
The cornerstone of treatment for SGC is surgical resec-
tion, but there are limited high-level data available to guide
adjuvant treatment recommendations. Based on retrospec-
tive studies, radiotherapy (RT) in the curative setting is gen-
erally recommended postoperatively for T3-T4 tumors,
high-grade histology, perineural or lymphovascular inva-
sion, close or positive surgical resection margins, and multi-
ple positive cervical lymph nodes (LNs), which are known
high-risk features for increased recurrence.3-6 Although RT
is widely accepted to improve locoregional control for
aggressive salivary cancers, it likely does not reduce the
risk of distant metastases,7 and its effect on survival is not
well characterized. Several previous analyses attempted to
address this with large databases,8-10 but these analyses had
varying degrees of limitations—including nonstandardized
surgical management of the regional LNs; not adjusting for
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immortal time bias, given that patients dying immediately
after surgery are unable to receive adjuvant therapy; inclu-
sion of numerous unknown covariables without imputation;
and the lack of a validity assessment for the Cox propor-
tional hazards assumptions.
In the present study, we explored the impact of postopera-
tive RT (PORT) with and without chemotherapy on survival
among patients with localized SGC who were undergoing
curative-intent resection and neck dissection per the National
Cancer Database (NCDB), using various statistical techniques
to mitigate the limitations of previous analyses. Moreover,
we performed subgroup analyses to try to identify factors
associated with a greatest benefit from PORT.
Material and Methods
Data Source
The NCDB is a hospital-based registry representing approxi-
mately 70% of all newly diagnosed cancer cases in the
United States. It comprises data from .1500 commission-
accredited cancer programs.11 The NCDB is a registry
maintained by the Commission on Cancer of the American
College of Surgeons and the American Cancer Society.
There are established criteria to certify the quality of
the submitted data, as well as an application process to
obtain the data. However, upon distribution of the data, the
Commission on Cancer of the American College of
Surgeons and the American Cancer Society are not respon-
sible for the analysis and conclusions presented in this arti-
cle. All data in this study were abstracted from the NCDB,
de-identified, and investigated, covering patients diagnosed
from 2004 to 2013. This study was deemed exempt by the
Cedars-Sinai Medical Center institutional review board.
Patient Selection
Our study included patients with nonmetastatic carcinoma of
the head and neck with salivary gland–specific histology
undergoing curative-intent surgical resection. We excluded
all squamous cell carcinomas even if they involved the major
salivary glands, given that these commonly represent LN
metastases from cutaneous head and neck sites. We also
required that all patients undergo neck dissection to minimize
bias related to pathologic nodal staging assessment and to
allow accurate matching and stage adjustment in multivari-
able models. We defined neck dissection as a procedure
yielding at least 10 LNs for pathologic assessment to exclude
more limited biopsies or incidentally detected LNs in the pri-
mary specimen.
We queried the NCDB for head and neck cancers
diagnosed between 2004 and 2013 with salivary histologies
(n = 34,959) according to the World Health Organization’s
classification.1,2 The CONSORT diagram (Consolidated
Standards of Reporting Trials) describes the patients
included in this analysis (see Supplemental Figure S1, avail-
able in the online version of the article). Patients with the
following characteristics were excluded: noninvasive histol-
ogy (n = 63), distant metastasis at presentation (n = 1850),
unknown follow-up details (n = 3536), no surgery at the
primary site (n = 186), unknown pathologic T classification
(n = 397), no documented LN staging (n = 12,364),
unknown number of LNs examined (n = 420), \10 LNs
examined (n = 10,354), RT received prior to surgery or
unknown timing of RT (n = 311), unknown RT dose (n =
326), and unknown details regarding the receipt of che-
motherapy (n = 795) or the timing of chemotherapy with
respect to RT (n = 73). We also excluded patients with ade-
nosquamous histology (n = 139), as this is regarded as a
malignancy of the surface epithelium and not the salivary
glands.2 This left 4145 patients, who formed the study cohort.
Multiple imputation was performed to account for missing
values of covariates. However, a confirmatory subgroup analy-
sis was performed for patients who had complete data for sig-
nificant predictors included in the model. Patients were
defined as receiving PORT if they received at least 50 Gy.
However, a sensitivity analysis was also performed defining
PORT as any radiation regardless of dose. Concomitant che-
moradiation (CRT) was defined as the initiation of chemother-
apy between the 14 days before the start of RT and the 14
days after. The 20% of patients treated at the highest-volume
facilities were defined as receiving treatment at high-volume
facilities; all other patients were considered to have received
treatment at lower-volume facilities.
Statistical Analysis
Missing data patterns for variables with missing values were
assessed and examined with the method proposed by
Little.12 Missing-ness rates were 26.5% for grade, 25.0% for
extranodal extension (ENE), and 4.7% for margins and were
found to be not missing completely at random. To reduce
the potential for bias, missing values were imputed by a
multiple imputation technique with fully conditional specifi-
cations implemented by the MICE algorithm described by
Van Buuren and Groothuis-Oudshoorn.13,14
The primary purpose of this study was to determine the
association of PORT with overall survival (OS) in SGC.
Baseline characteristics of patients undergoing surgery
alone versus PORT or CRT were compared with 2-sample
t tests for age and with chi-square tests for categorical cov-
ariates. The median follow-up time was calculated with the
reverse Kaplan-Meier method. The primary outcome was
OS calculated from the date of diagnosis to the date of
death or censored at last follow-up. Estimated survival func-
tions were generated via the Kaplan-Meier method and
compared with a log-rank test.
Univariate and multivariable survival analyses were per-
formed with the Cox proportional hazards model. Variable
selection was performed with a backward stepwise method,
with optimization for Akaike information criterion.15
Because the main covariate of interest, PORT, violated the
proportional hazards assumption as assessed by Schoenfeld
residuals, PORT was modeled as a time-varying coeffi-
cient.16 The extended Cox model was used in conjunction
with the Heaviside step function, where the extended Cox
model yields constant hazard ratios (HRs) for PORT among
different time intervals.17 We accomplished this by
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dichotomizing our data set into time-dependent epochs at 9
months and analyzing in a ‘‘counting process’’ format. The
cut point at 9 months was chosen because this cut point
resulted in the lowest Akaike information criterion with both
time segments satisfying the proportional hazards assumption.
The effect of PORT was then estimated with the extended
Cox model at 9 and .9 months from diagnosis.
Multicollinearity among covariates was assessed by the vari-
able inflation factor and deemed nonproblematic.
Because of the possibility of immortal time bias in a ret-
rospective study of adjuvant treatment (ie, patients need to
survive a certain amount of time after surgery to receive
PORT), we also performed landmark analyses including
only patients surviving 6 months to exclude those who
died prior to being able to complete PORT.
Propensity scores were calculated by fitting a multivari-
able logistic regression model, adjusting for covariates (see
Supplemental Table S1, available in the online version of
the article). Due to the imbalances of our treatment and con-
trol groups, caliper matching with a caliper of 0.01 was
used in conjunction with the nearest-neighbor algorithm to
improve the overall match result.18
Seven covariates of interest were assessed in subgroup
analyses for their interaction with the effect of PORT on
OS. A Bonferroni correction was applied, with a P value of
.007 (0.05/7) considered significant .
All statistical analyses were performed with R (version
3.4.0) with 2-sided tests and a significance level of .05.
Results
The baseline characteristics for the patients included in the
study are listed in Table 1. Patients receiving PORT had gen-
erally more aggressive features and were more likely to have
higher T-classification (P \ .001), higher N-classification
(P \ .001), high-grade tumors (P \ .001), positive surgical
margins (P\ .001), and ENE (P\ .001). Patients receiving
PORT were also more likely to be male (P \ .001), have
somewhat lower comorbidity (P = .007), and receive treatment
at nonacademic centers (P \ .001). In the group receiving
PORT, those receiving chemotherapy in addition to PORT
had generally more aggressive features (Supplemental Table
S1, available in the online version of the article), including
high-grade histology (81.7% vs 57.5%, P \ .001), T3-T4
tumors (68.5% vs 52.9%, P\ .001), N2-N3 disease (73.5%
vs 33.2%, P\ .001), ENE (55.6% vs 26.2%, P\ .001), and
positive margins (48.4% vs 33.3%, P\ .001).
The median follow-up time was 54 months. PORT was
associated with significantly improved OS after adjusting
for imbalances in other covariates in multivariable analysis
(Table 2), although no benefit was seen with the addition
of adjuvant chemotherapy (HR = 1.154; 95% CI, 0.994-
1.339; P\ .001). Because the effect of PORT varied over
time and violated the Cox proportion hazards assumption,
the effect of this variable was dichotomized into its effect
within the first 9 months after diagnosis (HR = 0.261; 95%
CI, 0.201-0.338; P\ .001) and the effect .9 months after
diagnosis (HR = 0.753; 95% CI, 0.657-0.863; P\ .001) in
the multivariable Cox model, with significant benefit seen
in both intervals.
In propensity score–matched cohorts, 5-year OS was
67.1% (95% CI, 64.0-70.4) with PORT and 60.6% (95% CI,
57.5-63.8) with surgery alone (P\ .001; Figure 1).
In subgroup analyses, PORT was associated with signifi-
cantly longer survival in virtually all subgroups of patients
after multivariable adjustment (Figure 2).
To mitigate any potential contribution of immortal time
bias, several sensitivity analyses were performed. In a land-
mark analysis of patients surviving at least 6 months after
diagnosis (Supplemental Table S2, available in the online
version of the article), PORT remained strongly associated
with improved survival in multivariable analyses (HR =
0.741; 95% CI, 0.653-0.841; P \ .001). Of note, the Cox
proportional hazards assumption was no longer violated for
PORT with this cohort. In propensity score–matched
cohorts, 5-year OS was 70.5% and 60.5% among patients
with and without PORT, respectively (Supplemental Figure
S1, available in the online version of the article). Similar
results were also observed when PORT was defined as any
radiation after surgery, irrespective of dose delivered, both
in the overall cohort (Supplemental Table S3, available in
the online version of the article) and in the landmark cohort
surviving at least 6 months (Supplemental Table S4 and
Figure S2, available in the online version of the article).
Discussion
In the present study, we show that PORT is associated with
a 6.5% increase in absolute 5-year OS in propensity score–
matched cohorts of patients with SGC who are undergoing
surgical resection and neck dissection. Notably, we found
that the magnitude of the survival effect associated with
PORT varied over time, requiring the use of time-varying
coefficients in our Cox regression model. The association of
PORT with longer survival was strongest within the first 9
months after diagnosis, with PORT associated with a rela-
tive mortality decrease of approximately 75% in comparison
with surgery alone. PORT continued to be associated with
improved survival beyond 9 months from diagnosis but with
a smaller relative decrease in mortality of 25%. This varia-
bility over time is possibly related to the natural history of
SGC, which includes multiple histologies that have a pro-
pensity for indolent distant metastasis and late relapse,19
potentially abrogating the survival impact of PORT at later
time points. We further confirmed that PORT was associ-
ated with longer survival in landmark analyses of patients
surviving at least 6 months after diagnosis to mitigate the
effect of immortal time bias. Our study provides one of the
largest and most statistically rigorous analyses supporting
the benefit of PORT in SGC to date.
The association of PORT with longer survival was seen
across essentially every subgroup in our study. Despite the
broad benefit from PORT for essentially all patients in our
study, it is important to note that we restricted our analysis
to patients undergoing neck dissections removing at least 10
LNs. Therefore, virtually all patients likely harbored 1
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Table 1. Baseline Characteristics of Patients with Salivary Gland Malignancies Undergoing Surgery with or without Postoperative Radiation
Therapy.
Patients, n (%)
Overall No Postoperative RT Postoperative RT P Value
Characteristics 4145 1560 2585
Age, y
65 2618 (63.2) 971 (62.2) 1647 (63.7) .359
.65 1527 (36.8) 589 (37.8) 938 (36.3)
Sex
Male 2309 (55.7) 785 (50.3) 1524 (59.0) \.001
Female 1836 (44.3) 775 (49.7) 1061 (41.0)
Race
White 3456 (83.4) 1294 (82.9) 2162 (83.6) .548
Black 449 (10.8) 179 (11.5) 270 (10.4)
Other 240 ( 5.8) 87 ( 5.6) 153 ( 5.9)
Charlson-Deyo Comorbidity Index
0 3398 (82.0) 1247 (79.9) 2151 (83.2) .007
1 597 (14.4) 241 (15.4) 356 (13.8)
2 150 ( 3.6) 72 ( 4.6) 78 ( 3.0)
Academic center
Nonacademic 1804 (43.5) 583 (37.4) 1221 (47.2) \.001
Academic 2341 (56.5) 977 (62.6) 1364 (52.8)
Facility volume
Low 3183 (76.8) 1178 (75.5) 2005 (77.6) .14
High 962 (23.2) 382 (24.5) 580 (22.4)
Insurance
None 150 ( 3.6) 52 ( 3.3) 98 ( 3.8) .001
Private 2059 (49.7) 745 (47.8) 1314 (50.8)
Medicaid 267 ( 6.4) 120 ( 7.7) 147 ( 5.7)
Medicare 1529 (36.9) 573 (36.7) 956 (37.0)
Other/unknown 140 ( 3.4) 70 ( 4.5) 70 ( 2.7)
Site
Parotid 2821 (68.1) 1042 (66.8) 1779 (68.8) \.001
Nonparotid major salivary gland 615 (14.8) 218 (14.0) 397 (15.4)
Oral cavity 398 ( 9.6) 203 (13.0) 195 ( 7.5)
Other minor salivary gland 311 ( 7.5) 97 ( 6.2) 214 ( 8.3)
Histology group
Mucoepidermoid carcinoma 1313 (31.7) 591 (37.9) 722 (27.9) \.001
Adenocarcinoma 1215 (29.3) 411 (26.3) 804 (31.1)
Adenoid cystic carcinoma 711 (17.2) 201 (12.9) 510 (19.7)
Salivary duct carcinoma 170 ( 4.1) 42 ( 2.7) 128 ( 5.0)
Acinic cell carcinoma 372 ( 9.0) 200 (12.8) 172 ( 6.7)
Other carcinoma, including ex-pleomorphic adenoma 364 ( 8.8) 115 ( 7.4) 249 ( 9.6)
Grade
Low 803 (19.4) 450 (28.8) 353 (13.7) \.001
Intermediate 1089 (26.3) 476 (30.5) 613 (23.7)
High 2253 (54.4) 634 (40.6) 1619 (62.6)
T-stage
T1 988 (23.8) 531 (34.0) 457 (17.7) \.001
T2 1089 (26.3) 414 (26.5) 675 (26.1)
T3 1018 (24.6) 291 (18.7) 727 (28.1)
T4 1050 (25.3) 324 (20.8) 726 (28.1)
(continued)
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high-risk features that prompted more extensive surgery.
Although our results strongly support PORT for all patients
with high-risk features, they cannot be extrapolated to
patients with lower-risk features who would not typically be
recommended to undergo neck dissection.
SGCs are generally considered radioresistant. However,
this notion comes predominantly from the disappointing
local control observed with definitive radiation for unresect-
able tumors.20 In contrast, our study adds to a growing body
of retrospective literature supporting radiation as a highly
efficacious treatment for salivary tumors in the setting of
microscopic disease. For example, in a study from the
Netherlands, PORT dramatically increased 10-year local
control in SGC by an absolute rate of 30% to 40% in
subgroups of patients with adverse pathologic features,
despite the fact that patients receiving surgery alone had
generally more favorable characteristics.6 Similarly pro-
found improvements in local control with PORT in SGC
were reported by other studies.21-23 In addition to control-
ling microscopic local disease, radiation seems to be very
effective at controlling microscopic regional disease as
well. For example, in a retrospective study from the
University of California, San Francisco, patients with sali-
vary cancers undergoing surgical resection without neck
dissection and PORT had 100% regional control at 10
years if elective neck irradiation was administered, as com-
pared with 74% without elective neck irradiation.26
Although several studies observed a survival benefit with
PORT in subsets of patients,21,25 it was not consistent.
This discrepancy may be related to the small size of most
series, given the rarity of this disease and the fact that
patients undergoing surgery with radiation typically have
more aggressive features as compared with patients treated
with surgery alone.
Our study showed no evidence of prolonged survival
associated with the addition of adjuvant chemotherapy. This
is similar to what was reported in several other retrospective
studies.26-28 However, because patients with SGC who are
undergoing adjuvant CRT typically have more high-risk fea-
tures than those undergoing adjuvant radiation alone, it is
difficult to draw definitive conclusions, and the role of
chemotherapy remains controversial. The benefit of conco-
mitant CRT in head and neck squamous cell carcinoma
is one of the most well-established concepts in all of oncol-
ogy,29-31 and it is possible that chemotherapy could radio-
sensitize SGC and provide at least a local control benefit.
An ongoing phase II/III trial, RTOG 1008, is testing this
hypothesis by randomizing patients with high-risk SGC
after surgery to radiation with or without weekly cisplatin.32
Other systemic therapies of molecularly targeted agents,
such as androgen deprivation therapy for androgen-receptor
positive tumors33 and Herceptin (trastuzumab) for HER2-
amplified tumors,34 may be promising agents to combine
with PORT in SGC, although this is challenging to test
given that it requires clinical trials involving a subset of an
already rare disease. Nevertheless, because the survival of
patients with SGC has not improved greatly over the past
several decades, developing systemic therapeutic strategies
to optimize locoregional control and eliminate micrometa-
static disease is a critical unmet need in SGC.35
There are multiple limitations of this study. First, this is
a retrospective observational study. Selection bias may
Table 1. (continued)
Patients, n (%)
Overall No Postoperative RT Postoperative RT P Value
N-stage
N0 2187 (52.8) 1036 (66.4) 1151 (44.5) \.001
N1 520 (12.5) 164 (10.5) 356 (13.8)
N2 1415 (34.1) 353 (22.6) 1062 (41.1)
N3 23 ( 0.6) 7 ( 0.4) 16 ( 0.6)
Extranodal extension
None 3057 (73.8) 1293 (82.9) 1764 (68.2) \.001
Positive 1088 (26.2) 267 (17.1) 821 (31.8)
Margins
Negative 2870 (69.2) 1224 (78.5) 1646 (63.7) \.001
Positive 1275 (30.8) 336 (21.5) 939 (36.3)
Chemotherapy
No 3570 (86.1) 1532 (98.2) 2038 (78.8) \.001
Yes 575 (13.9) 28 ( 1.8) 547 (21.2)
Year range
2004-2006 863 (20.8) 351 (22.5) 512 (19.8) .002
2007-2009 1123 (27.1) 452 (29.0) 671 (26.0)
2010-2013 2159 (52.1) 757 (48.5) 1402 (54.2)
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Table 2. Univariate and Multivariable Predictors of Outcome for Overall Survival among Patients with Salivary Gland Malignancies
Undergoing Surgery and Neck Dissection.
Univariate Survival Analysis Multivariable Survival Analysis
95% CI 95% CI




9 mo 0.402 0.311 0.519 \.001 0.261 0.201 0.338 \.001
.9 mo 1.401 1.234 1.591 \.001 0.753 0.657 0.863 \.001
Chemotherapy
No 1.000 1.000
Yes 1.826 1.594 2.092 \.001 1.154 0.994 1.339 .060
Age 1.040 1.036 1.044 \.001 1.027 1.021 1.033 \.001
Sex
Male 1.000 1.000
Female 0.605 0.542 0.676 \.001 0.899 0.800 1.011 .075
Race
White 1.000 1.000
Black 0.828 0.688 0.996 .045 1.104 0.912 1.337 .309
Other/unknown 0.548 0.412 0.729 \.001 0.638 0.476 0.855 .003
Charlson-Deyo Comorbidity Index
0 1.000 1.000
1 1.394 1.211 1.604 \.001 1.054 0.913 1.217 .474
2 2.077 1.659 2.600 \.001 1.621 1.288 2.040 \.001
Facility type
Nonacademic 1.000 1.000
Academic 0.839 0.755 0.932 .001 0.914 0.816 1.022 .116
Facility volume
Low volume 1.000 1.000
High volume 0.735 0.643 0.840 \.001 0.833 0.724 0.959 .011
Insurance status
Uninsured 1.000 1.000
Private 0.776 0.562 1.070 .122 0.776 0.560 1.076 .128
Medicaid 0.973 0.661 1.434 .891 1.021 0.690 1.510 .918
Medicare 1.936 1.408 2.661 \.001 0.928 0.660 1.304 .667
Other/unknown 1.044 0.679 1.606 .844 0.788 0.506 1.226 .291
Year of diagnosisa
2004-2006 1.000
2007-2009 1.016 0.885 1.167 .818
2010-2013 0.975 0.849 1.120 .724
Tumor site
Parotid 1.000 1.000
Nonparotid major salivary gland 1.063 0.915 1.234 .424 1.328 1.131 1.559 .001
Oral cavity 0.654 0.526 0.813 \.001 1.115 0.886 1.402 .353
Other minor salivary gland 0.811 0.652 1.008 .059 1.005 0.799 1.263 .968
Histologyb
Mucoepidermoid carcinoma 1.000
Adenocarcinoma 1.539 1.348 1.757 \.001
Adenoid cystic carcinoma 0.948 0.800 1.123 .535
Salivary duct carcinoma 1.697 1.315 2.191 \.001
Acinic cell carcinoma 0.719 0.565 0.913 .007
Other carcinoma, including ex-pleomorphic adenoma 1.523 1.256 1.847 \.001
(continued)
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exist, and the decisions to administer RT or decline it are
not always obvious. However, it is notable that virtually
every clinical and pathologic factor favored patients
receiving observation after surgery in comparison with
PORT, making it less likely that unmeasured confounding
variables—including known prognostic factors not captured
in the NCDB (eg, perineural invasion)—are driving the
results that we observed. Also, SGC is highly heterogeneous
in terms of histology, grade, and anatomic site. We adjusted
for these factors in all analyses, but unmeasured
Table 2. (continued)
Univariate Survival Analysis Multivariable Survival Analysis
95% CI 95% CI
Characteristic HR Lower Upper P Value HR Lower Upper P Value
Grade
Low 1.000 1.000
Intermediate 2.739 2.091 3.587 \.001 2.478 1.880 3.267 \.001
High 7.340 5.744 9.379 \.001 3.872 2.972 5.045 \.001
T-stage
T1 1.000 1.000
T2 2.166 1.776 2.642 \.001 1.584 1.294 1.939 \.001
T3 3.601 2.975 4.358 \.001 2.068 1.695 2.525 \.001
T4 4.865 4.045 5.852 \.001 2.752 2.264 3.345 \.001
N-stage
N0 1.000 1.000
N1 2.428 2.043 2.886 \.001 1.848 1.548 2.205 \.001
N2 4.819 4.262 5.448 \.001 3.124 2.724 3.583 \.001
N3 3.354 1.790 6.286 \.001 2.208 1.167 4.181 .015
Extranodal extensiona
None 1.000
Positive 2.744 2.469 3.050 \.001
Margins
Negative 1.000 1.000
Positive 1.889 1.698 2.102 \.001 1.296 1.158 1.450 \.001
Abbreviation: HR, hazard ratio.
aDropped from model.
bHistology site is adjusted by stratification.
Figure 1. (A) Overall survival of patients with salivary gland carcinoma, with or without postoperative radiation therapy, in propensity
score–matched cohorts. (B) Histogram of propensity scores before and after matching.
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heterogeneity could influence that benefit of PORT. Next,
we note that our results are not applicable to the large pro-
portion of indolent salivary tumors that do not require neck
dissection. Several important variables were not available
for all patients, including grade, ENE, and margins. We
accounted for these missing values by performing multiple
imputation. We excluded patients who did not undergo neck
dissections to ensure complete pathologic staging and allow
for more accurate matching between patients who did and
did not receive PORT. However, this limits the applicability
of our results to low-risk salivary cancers resected without
neck dissection. NCDB also lacks cancer-specific outcomes,
such as local control, regional control, and distant metasta-
sis. Despite these limitations, we believe that our
observation of improved survival associated with PORT in
SGC with surgical resection and neck dissection is robust.
Conclusions
PORT is associated with improved survival among patients
with SGC who are undergoing surgical resection and neck
dissection. Longer survival with PORT was seen for virtu-
ally all patients in our study, and when using landmark anal-
ysis to mitigate the effect of immortal time bias.
Importantly, these results are not applicable to low-risk
SGCs that do not require neck dissection. Notably, adjuvant
chemotherapy had no association with improved survival.
Future studies attempting to develop effective systemic ther-
apy regimens for sterilization of micrometastasis are needed
Figure 2. Multivariate Cox regression of the association of postoperative radiation with overall survival for patients with salivary gland car-
cinoma undergoing surgical resection and neck dissection in subgroups of interest. P values represent tests of interaction. Error bars indi-
cate 95% CI. ENE, extranodal extension; HR, hazard ratio; NOS, not otherwise specified.
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to further improve outcomes in this heterogeneous group of
diseases.
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